Biochemical Bone Markers in Prostate Cancer Patients with Local and Advanced Bone Metastates

Authors: HÜLYA AKSOY, YILMAZ AKSOY, FATİH AKÇAY, İSA ÖZBEY

Abstract: In the present study involving patients with bone metastases arising from prostate cancer, we measured urinary deoxypyridinoline (DPD) as a marker of collagen breakdown activity, serum total and bone-specific alkaline phosphatase activities and serum prostate specific antigen (PSA). This study included 20 patients with benign prostate hyperplasia (BPH) and 23 patients with carcinoma, 11 of had with bone metastases. DPD excretion in urine was significantly greater in prostate cancer patients with bone metastasis than in those with localised prostate cancer or BPH (p<0.001), but the difference between the localised prostate cancer and BPH groups was not significant (p>0.05). The serum markers of bone formation [total alkaline phosphatase (T-ALP) and bone ALP (B-ALP)] displayed higher mean concentrations in the group with positive bone metastases than in the group with local disease (p<0.001 for both). Serum T-ALP and B-ALP levels and urinary excretion of DPD were significantly correlated with the Soloway score (p=0.03, p=0.01 and p=0.01 respectively). Urinary DPD and serum B-ALP and T- ALP may provide useful information for supplementing PSA and bone-scan results in evaluating bone-metastatic activity.

Keywords: Prostate cancer, Deoxypyridinoline, Bone markers

Full Text: PDF